Oncology Penny Stocks

US-listed oncology penny stocks priced $0.50 to $5, ranked by today's percentage change. Cancer-focused drug developers, immuno-oncology, radioligand therapy, ADC platforms, CAR-T, and oncology-diagnostics plays. Updated intraday.

Data as of 8/29/2026 3:27:57 AM · Intraday prices · 108 penny stocks in theme
#SymbolCompanySectorPriceDay ChgVolume
1RNXTRenovoRx, Inc. Common StockHealthcare$1.6650+13.18%350K
2AIDX20/20 Biolabs, Inc. Common StockHealthcare$0.6360+6.47%120K
3BFRIBiofrontera Inc. Common StockHealthcare$1.5860+6.38%220K
4SRTSSensus Healthcare, IncHealthcare$3.5450+5.64%97K
5ATNMActinium Pharmaceuticals, IncHealthcare$1.0300+3.60%22K
6LIMNLiminatus Pharma, Inc. Class A Common StockHealthcare$4.4200+3.41%10K
7ALLRAllarity Therapeutics, Inc. Common StockHealthcare$1.4100+2.90%128K
8LNAILunai Bioworks Inc. Common StockHealthcare$2.3450+2.13%35K
9NTHINeOnc Technologies Holdings, Inc. Common StockHealthcare$4.7150+1.74%68K
10CLDICalidi Biotherapeutics, Inc.Healthcare$1.3190+1.54%5K
11CLDICalidi Biotherapeutics, Inc.Healthcare$1.3190+1.54%5K
12BYSIBeyondSpring Inc. Ordinary SharesHealthcare$0.6460+1.53%113K
13LUCDLucid Diagnostics Inc. Common StockHealthcare$0.9950+1.51%175K
14MGNXMacroGenics, Inc.Healthcare$4.1350+1.23%221K
15CATXPerspective Therapeutics, Inc.Healthcare$3.1570+0.90%811K
16NKTXNkarta, Inc. Common StockHealthcare$2.7350+0.73%143K
17AMSAmerican Shared Hospital ServicesHealthcare$1.4890+0.68%3K
18PHIOPhio Pharmaceuticals Corp. Common StockHealthcare$1.1300+0.45%17K
19TCRXTScan Therapeutics, Inc. Common StockHealthcare$0.7710+0.37%149K
20GOVXGeoVax Labs, Inc. NewHealthcare$0.6400+0.35%106K
21MDXHMDxHealth SA Ordinary SharesHealthcare$0.7050+0.21%268K
22ADCTADC Therapeutics SAHealthcare$1.1310+0.02%353K
23TVRDTvardi Therapeutics, Inc. Common StockHealthcare$1.83000.00%333K
24CRISCuris IncHealthcare$1.46700.00%116K
25TPSTTempest Therapeutics, Inc. Common StockHealthcare$1.07600.00%60K
26GNPXGenprex, Inc. Common StockHealthcare$3.64100.00%52K
27MRKRMarker Therapeutics, Inc. Common StockHealthcare$1.36500.00%43K
28PMCBPharmaCyte Biotech, Inc. Common StockHealthcare$0.51500.00%33K
29ERNAErnexa Therapeutics Inc. Common StockHealthcare$4.48500.00%26K
30BDMDBaird Medical Investment Holdings Ltd Ordinary ShareHealthcare$1.13000.00%24K
31CTORCitius Oncology, Inc. Common StockHealthcare$0.77500.00%22K
32ESLAEstrella Immunopharma, Inc. Common StockHealthcare$0.69400.00%20K
33XBIOXenetic Biosciences, Inc.Healthcare$3.93500.00%17K
34BCTXLBriaCell Therapeutics Corp. Warrant expiring 2031$0.95500.00%12K
35RNAZTransCode Therapeutics, Inc. Common StockHealthcare$2.16900.00%9K
36XBITXBiotech IncHealthcare$2.29000.00%7K
37CLRBCellectar Biosciences INC NEWHealthcare$2.59400.00%7K
38INTSIntensity Therapeutics, Inc. Common stockHealthcare$4.25000.00%6K
39BGMSBio Green Med Solution, Inc. Common StockHealthcare$0.86800.00%2K
40GDTCCytoMed Therapeutics Limited Ordinary SharesHealthcare$0.92400.00%893
41PAVMPAVmed Inc. Common StockHealthcare$4.97000.00%634
42INABIN8bio, Inc. Common StockHealthcare$1.0190-0.48%24K
43ONCYOncolytics Biotech, Inc. Common SharesHealthcare$0.8520-0.51%668K
44CSBRChampions Oncology, Inc.Healthcare$4.9500-0.70%3K
45MAIAMAIA Biotechnology, Inc.Healthcare$1.3750-0.72%344K
46INDPIndaptus Therapeutics, Inc. Common StockHealthcare$1.1200-0.86%49K
47ICCMIceCure Medical Ltd. Ordinary SharesHealthcare$2.2110-0.87%26K
48BOLDBoundless Bio, Inc. Common StockHealthcare$2.8600-1.05%73K
49HURATuHURA Biosciences, Inc. Common StockHealthcare$2.1290-1.17%41K
50ACTUActuate Therapeutics, Inc. Common stockHealthcare$1.6460-1.18%92K

Trading Sub-$5 Oncology

Oncology is the most catalyst-rich corner of biotech. Cancer trials produce frequent readouts, FDA decisions are highly visible, and a single Phase 1/2 hit can rerate a company 500-1,500%. The flip side: clinical holds and failed primary endpoints can wipe out 60-90% in a session. This is binary-event trading at its purest.

  • ASCO & ESMO conferences: major oncology conferences (May, September, June) are catalyst-dense windows. Abstracts publish 3-4 weeks before the meeting.
  • PDUFA dates: FDA action dates for cancer drugs are scheduled events — visible on FDA.gov.
  • Trial readout calendar: companies pre-announce expected readout windows; the windows themselves are the trade setup.
  • Indication breadth: companies with multiple cancer indications are more durable than single-asset plays. Platform technologies (ADCs, radioligands, bispecifics) command premiums.
  • Survival endpoints: overall survival (OS) is the gold standard; surrogate endpoints (PFS, response rate) are weaker. Pay attention to which the trial used.
  • Partnership leverage: a Big Pharma licensing deal can revalue a sub-$5 oncology company overnight.
  • Dilution constant: oncology development is expensive. Most sub-$5 names raise capital every 6-18 months — see our dilution explainer.
  • Halt risk on readout days: volatility halts (LUDP) are routine on trial-data days — see our halt guide.

See also: biotech penny stocks (broader), genomics penny stocks, penny stocks under $1.